Atika Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-48,000
| Closed | -$6.55M | – | 81 |
|
|
2024
Q4 | $6.55M | Buy |
+48,000
| New | +$6.55M | 0.7% | 40 |
|
|
2024
Q3 | – | Sell |
-44,500
| Closed | -$6.13M | – | 98 |
|
|
2024
Q2 | $6.13M | Sell |
44,500
-13,500
| -23% | -$1.86M | 0.6% | 51 |
|
|
2024
Q1 | $8M | Buy |
58,000
+8,000
| +16% | +$1.1M | 0.79% | 43 |
|
|
2023
Q4 | $6.59M | Sell |
50,000
-4,000
| -7% | -$527K | 0.88% | 45 |
|
|
2023
Q3 | $6.08M | Buy |
+54,000
| New | +$6.08M | 0.8% | 47 |
|
|
2020
Q1 | – | Sell |
-45,000
| Closed | -$4.84M | – | 87 |
|
|
2019
Q4 | $4.84M | Sell |
45,000
-12,000
| -21% | -$1.29M | 0.93% | 49 |
|
|
2019
Q3 | $5.14M | Sell |
57,000
-8,000
| -12% | -$721K | 1.08% | 37 |
|
|
2019
Q2 | $5.49M | Buy |
+65,000
| New | +$5.49M | 1.08% | 35 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 74 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 71 |
|
|
2016
Q1 | – | Sell |
-50,000
| Closed | -$2.83M | – | 49 |
|
|
2015
Q4 | $2.83M | Sell |
50,000
-23,500
| -32% | -$1.33M | 1.46% | 24 |
|
|
2015
Q3 | $2.92M | Buy |
73,500
+1,150
| +2% | +$45.8K | 1.43% | 26 |
|
|
2015
Q2 | $3.46M | Buy |
72,350
+21,150
| +41% | +$1.01M | 1.56% | 22 |
|
|
2015
Q1 | $2.03M | Buy |
51,200
+36,200
| +241% | +$1.44M | 1.36% | 34 |
|
|
2014
Q4 | $335K | Buy |
+15,000
| New | +$335K | 0.24% | 59 |
|